

REMARKS

Claims 68, 74, 80, 81, 87, 93, 99, 110-124 and new claims 125-136 are now pending in this application.

Claims 68, 74, 80, 81, 87, 93 and 99 were previously found to be allowable. These claims are now identified as "objected to" together with claims 110-124 in the Office Action Summary. It is assumed this designation is in error since no objection appears in the detailed action.

New claims 125-136 are directed to a pharmaceutically acceptable salt of a compound selected from subsets of the compounds listed in pending claims 68 and 124.

New claims 125-127 do not include the compound: *N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea. The inventorship for these claims is a subset of the original inventors and is different from the remaining claims. The inventors are:

RIEDL, BERND  
DUMAS, JACQUES  
KHIKE, UDAY  
LOWINGER, TIMOTHY  
SCOTT, WILLIAM  
SMITH, ROGER  
WOOD, JILL  
MONAHAN, MARY-KATHERINE  
NATERO, REINA and  
SIBLEY, ROBERT.

New claims 128 -130 do not include the compounds: *N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea and *N*-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea. The inventorship for these claims is also a subset of the original inventors and different from the remaining claims. The inventors are:

RIEDL, BERND  
DUMAS, JACQUES  
KHIKE, UDAY  
LOWINGER, TIMOTHY  
SCOTT, WILLIAM  
SMITH, ROGER  
WOOD, JILL  
MONAHAN, MARY-KATHERINE, and  
NATERO, REINA.

New claims 131-133 do not include the compounds: *N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea and *N*-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea. The inventorship for these claims is a subset of the original inventors and is also different from the remaining claims. The inventors are:

RIEDL, BERND  
DUMAS, JACQUES  
KHIKE, UDAY  
LOWINGER, TIMOTHY  
SCOTT, WILLIAM  
SMITH, ROGER  
WOOD, JILL  
NATERO, REINA and  
SIBLEY, ROBERT.

New claims 134-136 do not include the compounds: *N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea, *N*-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea, and *N*-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea. The inventorship for these claims is also a subset of the original inventors and different from the remaining claims. The inventors are:

RIEDL, BERND  
DUMAS, JACQUES  
KHIKE, UDAY  
LOWINGER, TIMOTHY  
SCOTT, WILLIAM  
SMITH, ROGER  
WOOD, JILL  
NATERO, REINA

#### Claim 74

Applicants traverse the rejection of claim 74 and maintain that it is not necessary to for this method claim to recite an “effective amount” of the compounds used or recite a “subject” to which the compounds are administered to satisfy the requirements of 35 U.S.C. § 112, second paragraph. There is no basis to restrict the methods defined to *in vivo* applications and there is no basis for requiring an amount of the active compound be specified, even an amount defined functionally. One skilled in the art will recognize that the

claim encompasses the use of any amount of the defined compounds in treating cancerous cell growth mediated by raf kinase.

**Information Disclosure Statement**

A new information disclosure statement will be submitted once copies of all references to be cited are obtained.

**SERIAL NUMBER 09/993,647, FILED 11/27/01;**

This application contains claims to the ureas from which the salts claimed herein are formed. An appeal brief was filed in this application. A copy of the Examiner's Answer is attached hereto.

**Other Copending Applications**

Other copending applications assigned to the same assignee as the present invention which were not cited earlier are listed below.

**SERIAL NUMBER 09/889,227, FILED 07/12/01;**

This application contains claims directed to urea compounds and their salts.

**SERIAL NUMBER 10/361,858, FILED 02/11/03;**

This application contains claims to methods of treating diseases with urea compounds and their salts.

**SERIAL NUMBER 10/789,446, FILED 03/01/04;**

This application contains claims directed to urea compounds and their salts.

**SERIAL NUMBER 10/788,029, FILED 02/27/04;**

This application contains claims directed to urea compounds and their salts.

**SERIAL NUMBER 10/788,405, FILED 3/1/04;**

This application contains claims directed to urea derivatives.

**SERIAL NUMBER 10/788,426, FILED 03/01/04;**

This application contains claims directed to urea compounds and their salts.

**SERIAL NUMBER 10/895,985, FILED 07/22/04;**

This application contains claims directed to a single urea and derivatives thereof.


**SERIAL NUMBER 10/848,567, FILED 05/19/04;**

This application contains claims directed to methods for treating diseases using ureas and their salts.

In view of the above, favorable reconsideration is courteously requested. If there are any remaining issues which can be expedited by a telephone conference, the Examiner is courteously invited to telephone counsel at the number indicated below.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

  
Richard J. Traverso, Reg. No. 30,595  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO &  
BRANIGAN, P.C.

Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-0025-A

Date: May 12, 2005

(RJT/dm) K:\Bayer\25\IRCE Submission.doc